Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Clinical impact of novel treatment strategies

Oncogene volume 21, pages 6970–6981 (2002)Cite this article

Abstract

Following two decades of research on the biology of cancer and in particular of lung cancer, we have now a large number of molecular targets that can be utilized to create specific medicines against these cancers. Non-small cell lung cancer represents numerically the most important solid tumor in Western world, and is poorly affected by current therapies, where surgery represents almost the only curative therapy for about 25% of patients who are resectable at diagnosis. An abundant number of targeted therapies are being investigated in NSCLC. Among them are the metalloproteinase inhibitors, several tyrosine kinase inhibitors and several attempts of gene replacement have also been made. Promising results have so far been obtained with some of these approaches, and the outcome of large randomized studies is awaited. Small cell lung cancer (SCLC) represents about 20% of lung carcinomas, and several of the novel approaches that are being attempted for NSCLC, are also being investigated for SCLC. All these novel therapies open a new era of anticancer treatment that will likely complement the currently available therapies in the near future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T . 1999 Clin. Cancer Res. 5: 1001–1005

  • Albelda SM . 1997 Chest 111: 114S–149S

  • Albelda SM, Wiewrodt R, Zuckerman JB . 2000 Ann. Intern. Med. 132: 649–660

  • Adlard JW . 2000 Anti-Cancer Drugs 11: 787–791

  • Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ . 1994 Cancer Res. 54: 3758–3765

  • Arteaga CL . 2001 J. Clin. Oncol. 19: 32s–40s

  • Askari FK, McDonnell WM . 1996 N. Engl. J. Med. 334: 316–318

  • Averbuch SD . 2002 Clin. Cancer Res. 8: 1–3

  • Bailey HH, Marnocha R, Arzoomanian R, Alberti D, Binger K, Vlokman J, Feierabend C, Ellingen S, Black S, Hampton K, Cooper M, Hott T, Wilding G . 2001 Proc. Am. Soc. Clin. Oncol. 20: 79a

  • Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J . 1998 [published erratum appears in Cancer Res 1999 Apr 15;59(8):2020] Cancer Res. 58: 2825–2831

  • Baselga J, Averbuch SD . 2000 Drugs 60: 33–40 discussion 41–42

  • Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J . 2000 J. Clin. Oncol. 18: 904–914

  • Baselga J, Yano S, Giaccone G et al . 2001 Clin. Cancer Res. 7: Suppl 11 630a

  • Bauer KS, Dixon SC, Figg WD . 1998 Bioch. Pharmacol. 55: 1827–1834

  • Blaese RM, Ishii-Morita H, Mullen C, Ramsey J, Ram Z, Oldfield E, Culver K . 1994 Eur. J. Cancer 30A: 1190–1193

  • Blanke CD, von Mehren M, Joensuu H, Roberts PJ, Eisneberg B, Heinrich M, Drucker B, Tuveson D, Dimitrijevic S, Silberman SL, Demetri GD . 2001 Proc. Am. Soc. Clin. Oncol. 20: 1a

  • Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J . 1997 Clin. Cancer Res. 3: 2099–2106

  • Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J . 1993 J. Natl. Cancer Inst. 85: 574–578

  • Camacho LH, Soignet SL, Pezzulli S, Canales C, Aghajanian C, Spriggs DS, Damle B, Sonnichsen D . 2001 Proc. Am. Soc. Clin. Oncol. 20: 79a

  • Carbone DC . 1997 Semin. Oncol. 24: 388–401

  • Carpenter G . 1987 Ann. Rev. Biochem. 56: 881–914

  • Carpenter G, Cohen S . 1990 J. Biol. Chem. 265: 7709–7712

  • Chambers AF, Matrisian LM . 1997 J. Natl. Cancer Inst. 89: 1260–1270

  • Chen C, Parangi S, Tolentino MJ, Folkman J . 1995 Cancer Res. 55: 4230–4233

  • Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G . 2000 Clin. Cancer Res. 6: 2053–2063

  • Clarke MR, Landreneau RJ, Finkelstein SD, Wu TT, Ohori P, Yousem SA . 1997 Human Pathol. 28: 54–59

  • Cohen RB, Falcey JW, Paulter VJ, Fetzer KM, Waksal HW . 2000 Proc. Am. Soc. Clin. Oncol. 19: 474a

  • Conry RM, LoBuglio A, Loechel F, Moore SE, Sumerel LA, Barlow DL, Curiel DT . 1995 Hum. Gene Ther. 2: 59–65

  • DeVore RF, Fehrenbacher L, Herbst RS, Langer CJ, Kelly K, Gaudreault J, Holmgren E, Novotny WF, Kabbinavar F . 2000 Proc. Ann. Meet. Am. Soc. Clin. Oncol. 19: 485a

  • Dang T, Johnson D, Kelly K, Rizvi N, Holmlund J, Dorr A . 2001 Proc. Am. Soc. Clin. Oncol. 20: 332a

  • Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC . 1999 Clin. Cancer Res. 5: 2773–2779

  • Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M . 2001a N. Engl. J. Med. 344: 1038–1042

  • Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . 2001b N. Engl. J. Med. 344: 1031–1037

  • Ennis B, Valverius E, Bates S, Lippman M, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J . 1989 Mol. Endocrinol. 3: 1830–1838

  • Escudier B, Le Chevalier T, Angevin F et al . 2000 Lung Cancer 29: Supp 1 184 (abstract 622)

  • Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M, European Organization for Research Treatment of Cancer Early Clinical Studies Group . 2001 J. Clin. Oncol. 19: 1167–1175

  • Fan Z, Baselga J, Masui H, Mendelsohn J . 1993 Cancer Res. 53: 4637–4642

  • Ferrara N, Bunting S . 1996 Curr. Opin. Nephrol. Hyperten. 5: 35–44

  • Ferrara N . 1999 J. Mol. Med. 77: 527–543

  • Figlin RA, Belldegrun A, Lohner ME, Roskos L, Yang X, Schwab G, Weiner LM . 2001 Proc. Am. Soc. Clin. Oncol. 20: 276a

  • Folkman J . 1995 N. Engl. J. Med. 333: 1757–1763

  • Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G . 1999 Cancer Res. 59: 99–106

  • Forgacs E, Zochbauer-Muller S, Olah E, Minna JD . 2001 Pathol. Oncol. Res. 7: 6–13

  • Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS . 1999 Lung Cancer 23: 191–207

  • Gatzemeier U, Groth G, Hirsh V . 2001 Eur. J. Cancer 37: Suppl 6 S50 (abstract 173)

  • Giatromanolaki A, Koukourakis MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC . 1996 Anticancer Res. 16: 3819–3825

  • Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP . 1990 Proc. Natl. Acad. Sci. USA 87: 6624–6628

  • Gordan MS, Talpaz M, Margolin K, Holmgren E, Sledge GW, Benjamin R, Stalter S, Sahk S, Adelman D . 1998 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 17: 210a

  • Grant SC, Kris MG, Houghton AN, Chapman PB . 1999 Clin. Cancer Res. 5: 1319–1323

  • Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A, Bonsignore G . 1999 Human Pathol. 30: 788–794

  • Halbert CL, Alexander IE, Wolgamot GM, Miller AD . 1995 J. Virol. 69: 1473–1479

  • Herbst RS, Kim ES, Harari PM . 2001 Expert. Opin. Biol. Ther. 1: 719–732

  • Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T . 1998a Cancer Res. 58: 3761–3764

  • Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P, Moody TW . 1998b Anticancer Res. 18: 775–782

  • Hidalgo M, Malik S, Rowinsky E, Miller A, Duffey D, de'Grafenried L, Siu L, Simmons C, Kreisberg J, Brattain M . 2001 Proc. Am. Soc. Clin. Oncol. 20: 71a

  • Holden SN, Eckhardt S, Fisher S, Persky M, Mikule C, O'Bryant CL, Morrow M, Richards H, Rodriguez S, Bol C, Cohen R . 2001 Proc. Am. Soc. Clin. Oncol. 20: 80a

  • Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A . 2000 Lung Cancer 30: 73–81

  • Human Gene Therapy Protocols. 1999 Hum. Gene Ther. 10: 2037–2088

  • Ichimura E, Maeshima A, Nakajima T, Nakamura T . 1996 Jpn. J. Cancer Res. 87: 1063–1069

  • Johnson D, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W . 2001 Proc. Am. Soc. Clin. Oncol. 20: 315a

  • Kenyon BM, Browne F, D'Amato RJ . 1997 Exp. Eye Res. 64: 971–978

  • Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA . 1990 Cancer Res. 50: 5184–5188

  • Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA . 1994 J. Clin. Invest. 93: 516–520

  • Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH . 2000 Nat. Med. 6: 879–885

  • Khuri FR, Rigas JR, Figlin R, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, Hong WK . 2001 J. Clin. Oncol. 19: 2626

  • Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB . 1998 Lung Cancer 22: 181–190

  • Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y . 1999 Proc. Natl. Acad. Sci. USA 96: 4995–5000

  • Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB . 1993 Science 260: 1934–1937

  • Kris MG, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, Feyereislova A, Ochs J, Averbuch S . 2000 Lung Cancer 29: Suppl 1 72

  • Krug LM, Miller VA, Crapanzano J, Ng KK, Pizzo B, Tyson L, McClean N, Azzoli CG, Heelan RT, Ginsberg M, Venkatraman E, Kris MG . 2001 Proc. Am. Soc. Clin. Oncol. 20: 333a

  • Kubba S, Schiller J, Slovis B, Coffee K, Worrell J, Thet L, Adak S, Mehta M, Johnson DH, Carbone D . 2000 Proc. Am. Soc. Clin. Oncol. 19: 487a

  • Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G . 2002 J. Clin. Oncol. 20: 1446–1448

  • Langer CJ, Adak S, Thor A, Vangel M, Johnson DH . 2001 Proc. Am. Soc. Clin. Oncol. 20: 315a

  • Levitzki A, Gazit A . 1995 Science 267: 1782–1788

  • LoRusso PM, Demchick L, Foster B, Knight J, Bissery MC, Polin LM, Leopold IIIWR, Corbett TH . 1996 Invest. New Drugs 14: 349–356

  • Margolin K, Gordon MS, Talpaz M, Fyfe G, Novotny W, Adelman D, Breed J . 1999 Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: 435a

  • Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM . 2000 Anti-Cancer Drug Design 15: 29–41

  • Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Yoshimura N, Takeda K, Tanigawara Y, Swaisland H . 2001 Proc. Am. Soc. Clin. Oncol. 20: 324a

  • Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM . 2000 J. Clin. Oncol. 18: 1135–1149

  • Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, Solano M, Stone M, Mallams J, Mues G . 1998 J. Clin. Oncol. 21: 155–160

  • Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL . 2000 J. Clin. Oncol. 18: 609–622

  • Nguyen DM, Wiehle SA, Koch PE, Branch C, Yen N, Roth JA, Cristiano RJ . 1997 Cancer Gene Ther. 4: 191–198

  • Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, The Japan Clinical Oncology Group . 2002 N. Engl. J. Med. 346: 85–91

  • O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S . 2000 Int. J. Cancer 86: 307–317

  • Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, Nicotra MR, Prat M, Maggi G, Arena N, Natali PG, Comoglio PM, Di Renzo MF . 1996 Br. J. Cancer 74: 1862–1868

  • O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J . 1994 Cell 79: 315–328

  • O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J . 1997 Cell 88: 277–285

  • Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ . 1997 Br. J. Surg. 84: 160–166

  • Perez-Soler R, Shin DM, Donato N, Radinsky R, Khuri F, Glisson BS, Shin H, Matsumoto T, Lawhorn K, Waksal H, Hong WK . 1998 Proc. Am. Soc. Clin. Oncol. 17: 1514

  • Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P . 2001 Proc. Am. Soc. Clin. Oncol. 20: 310a

  • Piccart-Gebhart MJ, Branle F, de Valeriola D, Dubuisson M, Hennebert P, Gil T, Forget F, Seifert W, Thibault A, Bol C, Awada A . 2001 Proc. Am. Soc. Clin. Oncol. 20: 80a

  • Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ . 1994 Oncogene 9: 1829–1838

  • Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ . 1999 Cancer Res. 59: 1347–1355

  • Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM . 2001 Invest. New Drugs 19: 1–11

  • Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ . 1999 Clin. Cancer Res. 5: 1658–1664

  • Rodenhuis S, Slebos RJC . 1990 Am. Rev. Respir. Dis. 142: S27–S30

  • Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, Hannah A . 1999 Proc. Am. Soc. Clin. Oncol. 18: 161a

  • Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D . 1996 Nat. Med. 2: 985–991

  • Roth JA, Cristiano RJ . 1997 J. Natl. Cancer Inst. 89: 21–39

  • Rowinsky EK, Windle JJ, Von Hoff DD . 1999 J. Clin. Oncol. 17: 3631–3652

  • Salgia R, Lynch TJ, Skarin AT et al . 2000 Lung Cancer 29: Suppl 1 186 (abstract 626)

  • Salomon DS, Brandt R, Ciardiello F, Normanno N . 1995 Crit. Rev. Oncol/Hematol. 19: 183–232

  • Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH . 2001 J. Clin. Oncol. 19: 448–457

  • Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C . 2001 J. Clin. Oncol. 19: 1750–1758

  • Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N . 1995 Cancer Res. 55: 5302–5309

  • Shawver LK . 1999 Tyrosine kinase inhibitors: from the emergence of targets to their clinical development In American Society of Clinical Oncology Educational Book Perry MC (ed) Lippincott, Williams & Wilkins: Alexandria VA pp. 29–47

    Google Scholar 

  • Shepherd FA, Giaccone G, Debruyne C, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krazkowski M, Zee B, Sadura A, Seymour L . 2001 Proc. Am. Soc. Clin. Oncol. 20: 4a

  • Shin DM, Nemunaitis J, Zinner RG, Donato N, Shin HJ, Myers J, Zhang P, Zengraft R, Khuri FR, Glisson BS, Eiseman I, Olson S, Bycott P, Lenehan PF, Hong WK . 2001 Proc. Am. Soc. Clin. Oncol. 20: 82a

  • Singhal S, Kaiser LR . 1998 Surg. Oncol. Clin. N. Am. 7: 505–536

  • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B . 1999 N. Engl. J. Med. 341: 1565–1571

  • Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG . 2000 Clin. Cancer Res. 6: 4885–4892

  • Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM . 2001 Blood 97: 1413–1421

  • Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Keller M, Stuart-Smith J, Knowles M, Clendeninn NJ, Shepherd F . 2001 Proc. Am. Soc. Clin. Oncol. 20: 307a

  • Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn Jr PA, Chou TC . 1999 Cancer Res. 59: 6178–6184

  • Stein CA, Narayanan R . 1994 Curr. Opin. Oncol. 6: 587–594

  • Stetler-Stevenson WG, Hewitt R, Corcoran M . 1996 Sem. Cancer Biol. 7: 147–154

  • Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam Jr JB, Richli WR, Savin M, Waugh MK . 1999 J. Natl. Cancer Inst. 91: 763–771

  • Teicher BA, Korbut TT, Menon K, Holden SA, Ara G . 1994 Cancer Chemother. Pharmacol. 33: 515–522

  • Thomas DA, Kantarjian HM . 2000 Curr. Opin. Oncol. 12: 564–573

  • Traxler P, Buchdunger E, Furet P, Gschwind H-P, Ho P, Mett H, O'Reilly T, Pfaar U, Thomas H . 1999 Clin. Cancer Res. 5: 3750S

  • Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, Gazdar AF . 1993 J. Natl. Cancer Inst. 85: 897–901

  • Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, Hung MC . 1995 J. Natl. Cancer Inst. 87: 682–684

  • Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K, Sano H . 2000 Anticancer Res. 20: 2867–2872

  • Verslype C, Van Steenbergen W, Humblet Y, Marse H, De Vis J, Palmer P, Seifert W, Bol C, Van Cutsem E . 2001 Proc. Am. Soc. Clin. Oncol. 20: 171a

  • Verweij J, Kehrer D, Planting A, de Jonge M, Eskens F, Klaren A, De Heus G, Palmer P, Bol C, Sparreboom A . 2001 Proc. Am. Soc. Clin. Oncol. 20: 81a

  • Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R . 2000 Oncogene 19: 3521–3528

  • Winquist E, Moore MJ, Chi K, Ernst S, Hirte H, Iscoe N, Venner P, Huan S, Powers J, Seymour L, Boucher T . 2001 Proc. Am. Soc. Clin. Oncol. 20: 197a

  • Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A . 1998 Cancer Res. 58: 4997–5001

  • Yang X, Jia X, Corvalan JR, Wang P, Davis CG . 2001 Crit. Rev. Oncol. Hematol. 38: 17–23

  • Yarden Y, Ullrich A . 1988 Ann. Rev. Biochem. 57: 443–478

  • Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC . 1994 Cancer Res. 54: 3260–3266

  • Yuen A, Halsey J, Fisher G, Advani R, Moore M, Saleh M, Ritch P, Harker G, Ahmed F, Jones C, Polikoff J, Keiser W, Kwoh TJ, Holmlund J, Dorr A, Sikic B . 2001 Proc. Am. Soc. Clin. Oncol. 20: 309a

  • Zeng-Rong N, Paterson J, Alpert L, Tsao MS, Viallet J, Alaoui-Jamali MA . 1995 Cancer Res. 55: 4760–4764

  • Zou Y, Zong G, Ling YH, Hao MM, Lozano G, Hong WK, Perez-Soler R . 1998 J. Natl. Cancer Inst. 90: 1130–1137

  • Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH . 2000 J. Clin. Oncol. 18: 927–941

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

    Giuseppe Giaccone

Authors
  1. Giuseppe Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Giaccone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giaccone, G. Clinical impact of novel treatment strategies. Oncogene 21, 6970–6981 (2002). https://doi.org/10.1038/sj.onc.1205565

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205565

Keywords

This article is cited by

Search

Advanced search

Quick links